DMS: Message from the Chairman – CEO of DMS Group – 09/14/2022 at 6:00 p.m.

Madam, Sir, dear shareholders,

During the last combined general meeting on July 18, 2022, the shareholders of Diagnostic Medical Systems Group wanted the establishment of a new governance with the aim of continuing the development of the group, by capitalizing on the skills of the teams in place, and to reposition shareholders at the center of the group’s objectives by instilling real stock market momentum.

In this perspective, the renewed Board of Directors which was held at the end of the general meeting appointed me President of the company with the mission of launching an ambitious action plan in order to allow the revaluation of the DMS Group action by implementing a strategy and financial communication that create value.

Since taking office, I have undertaken a strategic review of all of the Group’s activities. The first reflections lead us to consider refocusing DMS Group on its buoyant businesses, in order to take advantage of their development potential, while studying the opportunities for consolidation offered by the market.

Strengthening of DMS Imaging’s position as a major European player in medical imaging

With regard to our medical imaging division, the development of which I have been leading for almost ten years,

DMS Imaging

carried out a merger by way of partial contribution of assets to the Belgian company ASIT biotech (since renamed DMS Imaging) in early 2022. DMS Imaging is 88.33% owned by DMS Group.

This operation aims to create an independent European medical imaging company, an actor in the consolidation of the market, and a leading partner of the largest international medtechs.

Gathered in an ordinary general meeting on September 12, 2022, the shareholders of

DMS Imaging

implemented a new governance through a new Board of Directors, now made up of three members:

• Regis Roche
  
  – Chairman of the Board of Directors of DMS Imaging

• Samuel Sancerni
  
  – Managing Director, Managing Director of DMS Imaging

• Jean-Francois Gendron
  
  – Independent Director of DMS Imaging

The new DMS Imaging Board of Directors, to which I belong, wishes to set up a Strategic Council over the next few months with high-level personalities from the world of medical imaging or specialists in corporate strategy.

Over the coming semesters, we intend to pursue the following objectives:

• Strengthening of the position of a major European player in medical imaging
  
  DMS Imaging, via its flagship radiology products (Platinum DRF Adam and the new Platinum Neo table) in order to provide the medical imaging sector with the most advanced technologies, and our recognized expertise in bone densitometry;

• Realization of organic growth potential in order to reach a critical size
  
  , based in particular on our new production unit in Gallargues-le-Montueux as well as on the MC2 Project, which aims to develop two new high-end imaging solutions, which will be manufactured in France. The solutions resulting from this project, which benefits from funding by the French government as part of the Recovery Plan and the Future Investments Program (PIA), will thus strengthen the range of DMS Imaging products by to 2024 and 2025. These new solutions will support the future growth of DMS Imaging and will bring innovation and intelligence, both for medical personnel and for better patient diagnosis.
  
  We will also launch an ambitious project to redesign our range of bone densitometers with the aim of offering a greater value offer in the mid and high-end market segments;

• Listening to and supporting the consolidation movement in the imaging sector
  
  through new strategic and/or financial alliances and partnerships, in order to create a genuine French and European sector in medical imaging;

• Capitalize on the teams in place and their skills.
  
  Since 2015 we have greatly strengthened our management structure with business experts from process industries. These new skills, associated with the know-how of the historical teams, and the installation in our new factory allow us to calmly approach our future industrial and R&D challenges. I would particularly like to thank, through this word, all the employees of the Group.

Strategic reflections on the future of the DMS Biotech division

Regarding the division

DMS Biotech

which consists of a stake of around 40% in Hybrigenics and its subsidiaries (Stemcis, Adip’Sculpt and Inoviem Scientific), strategic discussions are currently under way on its future, in order to make the most of this asset as well for DMS Group and for the shareholders of Hybrigenics.

As a reminder, Hybrigenics owns several patented molecules under development and owns, through investments, the companies:

• stemcis
  
  specializing in the use of adipose stem cells in aesthetic and regenerative medicine;

• Inoviem Scientific
  
  CRO (
  
  contract research organization
  
  – contract research company)
  
  bio-analytical which allows the pharmaceutical industry, thanks to its patented technologies, to acquire greater precision in understanding the clinical mode of action (MoA) of a drug candidate and thus to “secure” clinical trials ;

• B-Cell Design
  
  a subsidiary of Inoviem Scientific specializing in new generation monoclonal antibodies.

The result of these reflections will be shared with shareholders and employees as part of a communication aimed at detailing DMS Group’s strategic plan which will be carried out during the month of October, after the publication of the 2022 half-year results, on September 30, 2022, and at the Journées Francophones de Radiologie 2022 which will take place from October 7 to 10, 2022.

Project of free allocation of share subscription warrants to thank the shareholders of DMS Group

In order to thank the shareholders who have accompanied it for a long time on the various stages of its development, DMS Group is currently studying a project to issue and allocate free stock warrants (BSA) to its shareholders. .

Further details on the terms of this proposed operation will also be communicated in the coming weeks.

Thank you for your confidence and I look forward to seeing you in October for the detailed presentation of the DMS Group strategic plan.

Samuel Sancerni

Chairman – Managing Director of DMS Group

About DMS Group

DMS-Group

is made up of companies with strong innovation potential. Historically centered on the medical imaging industry, the activity is gradually expanding into new horizons. By investing in the future and betting on research, DMS Group hopes to provide the solutions of tomorrow.

• Specialized in high technology at the service of medical diagnosis,
  
  DMS Imaging
  
  is now positioned as the French leader in the development, design and manufacture of imaging systems dedicated to radiology, bone densitometry, 3D modeling and posturology. DMS Imaging (formerly ASIT Biotech) is listed on the Euronext Brussels and Euronext Paris markets (ISIN: BE0974289218 – ticker: DMSIM).

• DMS Biotech
  
  , made up of Hybrigenics and its subsidiaries, carries the group’s development strategy in the field of biotechnologies, and particularly technologies for the treatment of osteoarthritis and regenerative medicine based on the injection of adipose stem cells. Hybrigenics is listed on the Euronext Growth market in Paris (ISIN: FR0004153930 – ticker: ALHYG).

DMS Group is present on all continents through a network of more than 140 national distributors, subsidiaries and joint ventures.

DMS Group is listed on the Euronext Growth market in Paris (ISIN: FR0012202497 – ticker: ALDMS).

More information on

www.dms.com

.

RECEIVE ALL DMS GROUP FINANCIAL INFORMATION FOR FREE BY EMAIL BY SUBSCRIBING TO

WWW.ACTUSNEWS.COM

.

contacts

© Copyright Actusnews Wire

Receive the company’s next press releases free of charge by email by subscribing to www.actusnews.com